CLOs on the Move

TCR2

www.tcr2.com

 
TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR²`s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.tcr2.com
  • 100 Binney Street Suite 710
    Cambridge, MA USA 02142
  • Phone: 617.949.5200

Executives

Name Title Contact Details
Viera Muzithras
 Vice President of Regulatory Affairs Profile

Similar Companies

Mandalmed

Mandalmed is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Symborg

Ayudamos a los agricultores a maximizar sus cosechas con el mínimo de recursos y sin riesgos para la salud humana, animal y del medioambiente

Macherey-Nagel

Macherey-Nagel is a Easton, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Reflex Photonics

Reflex Photonics Inc. is a Sherbrooke, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Novascreen Biosciences Corporation

Novascreen Biosciences Corporation is a Hanover, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.